Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer
Advanced Colorectal Cancer
DRUG: Raltitrexed|DRUG: Irinotecan|DRUG: Oxaliplatin|DRUG: Bevacizumab
PFS, Progression Free Survival, 6 months
OS, Overall Survival, 15 months|ORR, Objective Response Rate, 36 months|DCR, Disease Control Rate, 36 months|AEs, Percentage of participants experiencing grade 3-5 adverse events, 36 months
The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer